Prevenar 13 is named as an intervention in 2 current clinical trials in our China and France registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Fosun Adgenvax Biopharmaceutical Co.,Ltd (1). The most-studied condition is Streptococcus Pneumoniae Infection.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
NCT04460235 · ClinicalTrials.gov ↗ · Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin
|
Phase 4 | Recruiting | Poitiers University Hospital | France |
|
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
NCT05759520 · ClinicalTrials.gov ↗ · Streptococcus Pneumoniae Infection
|
Phase 3 | Active, closed | Fosun Adgenvax Biopharmaceutical Co.,Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Fosun Adgenvax Biopharmaceutical Co.,Ltd | 1 |
| Poitiers University Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in France | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and France registers name Prevenar 13 as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in France. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Fosun Adgenvax Biopharmaceutical Co.,Ltd (1) and Poitiers University Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prevenar 13 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prevenar 13 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prevenar 13 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.